These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 20129254

  • 1. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ, Setter SM.
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B, Schweizer A, Dejager S.
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [Abstract] [Full Text] [Related]

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 4. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 5. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S, Raccah D, Schweizer A, Dejager S.
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [Abstract] [Full Text] [Related]

  • 6. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E.
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [Abstract] [Full Text] [Related]

  • 7. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S, Choe HM, Sweet BV.
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [Abstract] [Full Text] [Related]

  • 8. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ, Jobe LJ, Martin R.
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
    Thompson AM, Linnebur SA, Vande Griend JP, Saseen JJ.
    Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
    [Abstract] [Full Text] [Related]

  • 14. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH.
    Am J Ther; 2011 Feb; 18(2):117-52. PubMed ID: 19834322
    [Abstract] [Full Text] [Related]

  • 15. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM, Maggi S, Paolisso G.
    Drugs Aging; 2008 Feb; 25(11):913-25. PubMed ID: 18947259
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.